The Laboratory of Cancer Biology develops smart cancer therapeutics with increased potency and decreased side effects.
Our mission is to change the perception of cancer as being a largely incurable disease. We use in vivo peptide phage display screens to identify homing peptides that bind to specific targets in the vasculature. Corresponding synthetic peptides are explored for targeting drugs, biologicals, and nanoparticles into tumors to increase their therapeutic index. We focus on development of novel diagnostic tests and therapeutics for the early detection and precision treatment of solid tumors (glioblastoma, and breast, prostate ovarian, prostate, and colorectal carcinoma). Our lab is also at the forefront of development of next generation peptidic shuttles capable of efficient and high capacity payload delivery across the blood brain barrier.
Silver Nanocarriers Targeted with a CendR Peptide Potentiate the Cytotoxic Activity of an Anticancer Drug
Written on Wednesday, 05 August 2020 11:50We report application of affinity-targeted silver nanoparticles (AgNPs) for selective delivery and potentiation of the activity of cytotoxic compound, monomethyl auristatin E (MMAE), in malignant…
Collaborative studies link CendR pathway to SARS Coronavirus-2 infection and spreading.
Written on Friday, 03 July 2020 10:32Our discovery of the CendR tissue transport pathway in 2009 raised the fascinating question of the physiological function of this pathway. It has become increasingly…
Collaborative reports with Prof. Santos and Prof. Salonen in Finland and Prof. Mougdil in the USA.
Written on Thursday, 04 June 2020 11:11Collaborative studies in interdisciplinary fields, such as nanomedicine, are critical for developing synergies and robust translationally relevant platforms. Recently, our team participated in highly rewarding…
Exposed CendR Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa
Written on Thursday, 09 July 2020 10:56Pemmari T, Ivanova L, May U, Lingasamy P, Tobi A, Pasternack A, Prince S, Ritvos O, Makkapati S, Teesalu T, Cairo MS, Järvinen TAH, Liao…Read more...
Targeting Pro-Tumoral Macrophages in Early Primary and Metastatic Breast Tumors With the CD206-Binding mUNO Peptide
Written on Thursday, 04 June 2020 11:48Lepland A, Asciutto EK, Malfanti A, Simón-Gracia L, Sidorenko V, Vicent MJ, Teesalu T, Scodeller P. Mol Pharm. 2020 Jun 1. doi: 10.1021/acs.molpharmaceut.0c00226. Online ahead…Read more...
OctoberPeptide targeted polymersomes bind to M2 human macrophagesPolymersomes targeted with an M2 macrophage binding peptide (green) identified in our lab using phage display bind to and are taken up by M2s (red) originated from human primary monocytes.…
SeptemberPolymersomes targeted with an M2 macrophage binding peptide in a mouse model of triple negative breast cancerPolymersomes targeted with an M2 macrophage binding peptide (green) identified in our lab using phage display home to M2 TAMs (red) after intravenous administration in a mouse model of triple…
JanuaryHigh infiltration of CD206+ cells in human breast tumorsImmunohistochemical staining of human CD206 (brown) with nuclear counterstain (Hematoxilin, in dark blue). Authors: Anni Lepland and Pablo Scodeller.